glp-1 drugs key developments 2025 GLP-1s in 2025: Who's Using Them, Who's Covering Them, and What's Next GLP-1 vs oncology market: Keytruda

Olsson, M

Neoplasia 13 , 8191 (2008)

484,485 UPS dysregulation in SLE: autoantibodies, antigen processing, and immune signaling In SLE, aberrant UPS activity contributes to inflammatory pathways, defective antigen presentation, and impaired apoptotic processes

Most protocols follow a pattern like: Start at a low dose Increase every few weeks if you are tolerating it well Adjust pace based on side effects and progress Some people feel appetite changes within the first 12 weeks, but meaningful weight change typically builds over time

Published guidance recommends aspirating before injection to check for blood return, though this practice is debated in current literature

Although GLP-1RAs are generally well tolerated, there are some circumstances in which this drug class is not recommended